Carmell Corp. Stock Plummets to New 52-Week Low of $0.82

Carmell Corp., a microcap player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 0.82 on September 17, 2025. This significant decline reflects a challenging year for the company, with its stock price plummeting by 58.4% over the past year, contrasting sharply with the S&P 500's performance of 17.28% during the same period.
Carmell Corp. operates within a highly competitive industry, and its current market capitalization stands at approximately USD 4 million. The company has not reported any earnings, as indicated by its loss-making status, and it does not offer a dividend yield. Financial metrics reveal a debt-to-equity ratio of 0.39, suggesting a moderate level of leverage, while an impressive return on equity of 152.26% indicates effective management of shareholder equity despite the overall stock performance.

The stock's previous 52-week high was recorded at USD 38.1, highlighting the stark contrast to its current valuation. As Carmell Corp. navigates this challenging landscape, its performance metrics will be closely monitored by market participants.